I've been really busy lately, and I've had a hard time finishing any blog posts. There is actually a bunch of interesting news on Follicular Lymphoma lately, and I've been trying to sort through it see what's worth writing about.
So for now, here's a link to another short video from OncLive called "Dr. Salles on New Agents Being Investigated in Follicualr Lymphoma."
It features Dr. Gilles Salles discussing briefly (it's only a 1 minute 19 second video) some of the more recent treatments being approved and tested: PI3 kinase inhibitors like Idelalisib and Duvelisib (which seem to help a particular group of patients with responses of a year or so), BTK inhibitors like Ibrutinib
(again, a particular group seems to get help from this), and some immunotherapy treatments (which he thinks will be effective in combinations with other treatments).
That's all I have for now, but maybe it will satisfy whatever Follicular Lymphoma cravings you have for now.
More soon -- I promise.
Gilles
Salles MD, PhD, Centre Hospitalier Lyon-Sud, discusses new agents being
investigated for patients with follicular lymphoma.
PI3 kinase inhibitors are currently of interest in patients with follicular lymphoma who have failed prior therapy. A select group of patients will benefit from these drugs and the response generally lasts for 1 year.
A small portion of patients respond to BTK inhibitors, such as ibrutinib (Imbruvica), but only some of the responses are long lasting, explains Salles.
Additionally, immunotherapy has not had much activity as a single agent, but combinations are currently being investigated for patients with follicular lymphoma.
- See more at: http://www.onclive.com/onclive-tv/dr-salles-on-new-agents-being-investigated-in-follicular-lymphoma#sthash.L9RaWgOH.dpuf
PI3 kinase inhibitors are currently of interest in patients with follicular lymphoma who have failed prior therapy. A select group of patients will benefit from these drugs and the response generally lasts for 1 year.
A small portion of patients respond to BTK inhibitors, such as ibrutinib (Imbruvica), but only some of the responses are long lasting, explains Salles.
Additionally, immunotherapy has not had much activity as a single agent, but combinations are currently being investigated for patients with follicular lymphoma.
- See more at: http://www.onclive.com/onclive-tv/dr-salles-on-new-agents-being-investigated-in-follicular-lymphoma#sthash.L9RaWgOH.dpuf
Dr.
Salles on New Agents Being Investigated in Follicular Lymphoma - See
more at:
http://www.onclive.com/onclive-tv/dr-salles-on-new-agents-being-investigated-in-follicular-lymphoma#sthash.L9RaWgOH.dpufDr
Dr.
Salles on New Agents Being Investigated in Follicular Lymphoma - See
more at:
http://www.onclive.com/onclive-tv/dr-salles-on-new-agents-being-investigated-in-follicular-lymphoma#sthash.L9RaWgOH.dpuf
2 comments:
Thank you!
Donna
👍
Post a Comment